<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/7B26620B-FEB9-4EF6-884F-8670FC59E3D6"><gtr:id>7B26620B-FEB9-4EF6-884F-8670FC59E3D6</gtr:id><gtr:firstName>David</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Brooks</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1100810"><gtr:id>738A7EA2-B93E-47AA-AF54-59581F40B06F</gtr:id><gtr:title>Neurology</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1100810</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:technicalSummary>This programme, based at Imperial College London, targets the use of positron emission tomography (PET) to image the functional changes associated with Alzheimer?s, Parkinson?s, and Huntington?s diseases. 
In subjects who have amnestic mild cognitive impairment and so are at risk of progressing to dementia the time course of amyloid deposition and microglial activation (inflammation) and relationship between these pathologies is being examined. Brain imaging findings with PET are being correlated with amyloid and cytokine levels in spinal fluid and plasma proteomic profiles. The time course and pattern of amyloid deposition in carriers of gene mutations predisposing to Alzheimer?s disease (presenelin and APP) is also being tracked. The efficacy of anti-amyloid strategies such as passive immunotherapies is being trialled using PET amyloid imaging as a proof of mechanism.
Parkinson?s disease (PD) patients with memory or gait difficulties are also at risk of developing dementia. Again, the prevalence of cortical microglial activation and amyloid deposition in these high risk cases and the relationship between these pathologies is being examined. Asymptomatic LRRK2 and glucocerebrosidase A gene mutation carriers at risk for PD are also being ascertained to determine the time course of inflammatory changes in the brainstem. PD is also associated with other non-motor problems such as sleep disorders, fatigue, depression, and impusle control disorders. PET is being used to study the relative contributions of brainstem and limbic dopaminergic and serotonergic dysfunction to these syndromes in PD in the belief that it may throw light on the mechanisms underlying these problems in the general population. The implantation of fetal midbrain cells into the putamen of advanced PD patients has previously been associated with variable efficacy and disabling graft-associated involuntary movements (dyskinesias). We are studying the mechanisms underlying development of thesias. Additionally, a trial using PET to measure graft function in transplanted patients with early rather than advanced PD is underway. 
Huntington?s disease (HD) gene carriers inevitably develop symptoms but it is now possible to detect functional changes with PET some years ahead of clinical disease manifestation. The programme is examining the time course of striatal microglial activation in asymptomatic HD gene carrtiers and how this correlates with spinal fluid and plasma levels of cytokines and other inflammatory markers. The role of cannabinoid CB1 radioligands as markers of striatal degeneration in HD is also being explored. 
In summary, this MRC programme is designed to determine the efficacy of functional imaging as a prognostic biomarker of dementia, to determine the role of microglial activation in driving neurodegeneration, and to provide proof of mechanism when putative neuroprotective and restorative therapies are being trialled.</gtr:technicalSummary><gtr:fund><gtr:end>2017-05-04</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-05-05</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1551766</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>MHRA</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D1F8E713-B71D-4F99-B423-C0D75263C523</gtr:id><gtr:impact>3rd MRC MHRA PET Expert Panel Meeting, London, 31 May 2012

Participant in panel meeting.

N/A</gtr:impact><gtr:outcomeId>DqevPJmGF6v</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>EFNS</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A692FAAB-C02A-47F5-88AF-5448527547A0</gtr:id><gtr:impact>16th European Federation of Neurological Societies, Stockholm, September 2012
Title: Monitoring treatment effects in neurological disorders: the role of neuroimaging techniques


N/A</gtr:impact><gtr:outcomeId>XZsZmZC9Twu</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nottingham</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BB809514-8222-45A5-9B2F-FBD245443B28</gtr:id><gtr:impact>Queens Medical Centre, Department of Neurology, Nottingham, July 2012
Title of talk: Imaging non-motor symptoms of Parkinson's disease

N/A</gtr:impact><gtr:outcomeId>FmFWNnhvvNv</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>World Congress of Neurology</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>541F7F6F-BAAE-4A23-A54A-031BBAC27A53</gtr:id><gtr:impact>XXth World Congress of Neurology, Marrakesh, November 2012 
&amp;quot;Imaging og motor and non-motor symptoms. In &amp;quot;Parkinson's disease re-visited&amp;quot;

N/A</gtr:impact><gtr:outcomeId>J6XYwneBMNp</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDPD</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>2E55BCDE-3CE3-4A81-BE7C-ECE08E5F5C79</gtr:id><gtr:impact>MD PD Meeting, Berlin, May 2012
Title of talk: Imaging non-motor symptoms in Parkinson's disease.
Title of talk: The role of amyloid in Parkinson's disease

N/A</gtr:impact><gtr:outcomeId>bWYJtjh9CnM</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Movement Matters - PD Awareness</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7DCD8D35-7F0C-4DED-935A-410123F0D99A</gtr:id><gtr:impact>Web Chat lasted for more than an hour.

Invited to give presentation.</gtr:impact><gtr:outcomeId>5463378b5f88d7.51189499</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Network</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>2FBFCE06-BBA8-4416-BA8C-D687A817665C</gtr:id><gtr:impact>Question and answer and discussions followed.

Invited to give talks.</gtr:impact><gtr:outcomeId>54633c648d4f58.09250030</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ENS</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3E224D9B-1825-42BF-8B84-90D435D8D969</gtr:id><gtr:impact>European Neurological Society, Prague, June 2012
Title of talk: Parkinson's disease and parkinsonism. Neuroimaging and early diagnosis of neurological diseases

N/A</gtr:impact><gtr:outcomeId>MX3BxY6UJuJ</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Groningen</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>63CC4EAF-E7A1-4C7B-910A-EB2BAE0983B4</gtr:id><gtr:impact>University of Groningen - Intrnational meeting on SPECT and PET in Neurology and Psychiatry.
Title of talk: Imaging the translocator protein.

N/A</gtr:impact><gtr:outcomeId>JkpsieqUsVr</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Media Interest (PPMI study)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>3E060864-562F-40F5-BD1E-4277F34DAFD9</gtr:id><gtr:impact>Increased interest and enquiry in our research.

People volunteering for our research.</gtr:impact><gtr:outcomeId>5463367f1a7844.00731373</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Research Trust visit</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>AEF53AC8-37F4-4F5C-88C1-669E58481803</gtr:id><gtr:impact>6 supporters and 2 staff from the Alzheimer's Research Trust attended the unit. A presentation was given on the work that is done using their grant which is also supported in part by the MRC. They had a tour of the facilities where the scanning take place and chatted with researchers involved.

Charities do this as a way of helping them to raise money for future research.</gtr:impact><gtr:outcomeId>QECPZzBbuLx</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Poster Presentation</gtr:presentationType><gtr:primaryAudience>Supporters</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>MDS</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>3938FCC3-FF64-44C1-8E1B-0C513C1ECAA3</gtr:id><gtr:impact>Movement Disorder Society, Dublin, June 2012
Title of talk: Neuroimaging in mild cognitive impairment and Parkinson's disease dementia

N/A</gtr:impact><gtr:outcomeId>AmaHXwjSNJi</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ECNP</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>62829DD9-C5F3-41A5-93A6-786051D0B25A</gtr:id><gtr:impact>European College of Neuropsychopharmacology, Vienna, October 2012
Title of talk: Dopamine dysregulation and pathological gambling. Insights from imaging Parkinson's disease.

N/A</gtr:impact><gtr:outcomeId>WbjFMsMxMaA</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>University of Wales</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>96181CC1-1A94-4897-B3A9-2CF3F1C496AA</gtr:id><gtr:impact>University of Cardiff - Advances in Clinical Neuroimaging November 2011
Title: Imaging Alzheimer's disease. In &amp;quot;Advances in clinical neuroimaging&amp;quot;

N/A</gtr:impact><gtr:outcomeId>C91geuHvJhB</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Other academic audiences (collaborators, peers etc.)</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Overseas Charity - MJFF</gtr:description><gtr:end>2018-09-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:fundingRef>PPMI (P34459)</gtr:fundingRef><gtr:id>15FF0659-2B1F-4FA4-A2E2-D200C7374666</gtr:id><gtr:outcomeId>5461e0dfa8a594.95799462</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2010-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>249688</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Overseas Charity - MJFF</gtr:description><gtr:end>2015-01-02</gtr:end><gtr:fundingOrg>Michael J Fox Foundation</gtr:fundingOrg><gtr:fundingRef>P36587</gtr:fundingRef><gtr:id>CA4C1A6A-AC7E-4947-BC77-49975B79BD3C</gtr:id><gtr:outcomeId>ZbLxdCVMbr1</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>14000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Dementias and Neurodegenerative Diseases Research Network (DeNDRoN)</gtr:department><gtr:description>Dendron</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>Northamptonshire Healthcare NHS Foundation Trust</gtr:fundingOrg><gtr:fundingRef>P48533</gtr:fundingRef><gtr:id>E1F88669-C1E0-4153-8069-9438D33058BB</gtr:id><gtr:outcomeId>QrKdi61DKFX</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>18000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Imperial Biomedical Research Centre</gtr:department><gtr:description>NIHR (BRC) Pilot Project Competition</gtr:description><gtr:end>2014-09-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>ACC15BEA-EFBC-464C-A7B7-20E11334E634</gtr:id><gtr:outcomeId>KTH1nx9Tssf</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>Germany, Federal Republic of</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Institute of Human Genetics</gtr:department><gtr:description>FP7 (INMiND)</gtr:description><gtr:end>2017-02-02</gtr:end><gtr:fundingOrg>Justus Liebig University Giessen</gtr:fundingOrg><gtr:fundingRef>P39724</gtr:fundingRef><gtr:id>E9EDA996-EF92-4A8C-A4E5-8E4B05DD65D7</gtr:id><gtr:outcomeId>BbPEe7MApGp</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>220820</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Imperial Biomedical Research Centre</gtr:department><gtr:description>NIHR Imperial biomedical Research Centre(BRC)Funding Award</gtr:description><gtr:end>2015-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:fundingRef>P45827</gtr:fundingRef><gtr:id>1E86FD1F-FD1D-45FC-8ADE-938695A19CF3</gtr:id><gtr:outcomeId>fZuLeoWN7cX</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-06-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>7E68E99E-58D0-4468-8C2F-7CD6B1A49047</gtr:id><gtr:title>Imaging biomarkers in tauopathies.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c8b08d49174e6d5e5a8d728685a6b390"><gtr:id>c8b08d49174e6d5e5a8d728685a6b390</gtr:id><gtr:otherNames>Dani M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn><gtr:outcomeId>56b096c688fba0.85344074</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>291A636C-F5AF-421A-B32C-CD0869FEA932</gtr:id><gtr:title>Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4752b222bbdee97e09071550d9255907"><gtr:id>4752b222bbdee97e09071550d9255907</gtr:id><gtr:otherNames>Fan Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>5457975dbc14e2.30217987</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8420BA7B-56DA-4365-A363-4BD759585860</gtr:id><gtr:title>Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions.</gtr:title><gtr:parentPublicationTitle>Alzheimer's &amp; dementia : the journal of the Alzheimer's Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/193668764a5f7c21dd27965e246dd888"><gtr:id>193668764a5f7c21dd27965e246dd888</gtr:id><gtr:otherNames>Varley J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1552-5260</gtr:issn><gtr:outcomeId>5655901d4cc765.62330377</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7AA55E1-8623-42C7-A330-FAB136BD9822</gtr:id><gtr:title>Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid ?-amyloid 42: a cross-validation study against amyloid positron emission tomography.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f172ca51b3e5d44d83d1009531076e19"><gtr:id>f172ca51b3e5d44d83d1009531076e19</gtr:id><gtr:otherNames>Palmqvist S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>5457984bd65c38.85080321</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8594394E-AF65-48C1-9F5E-EAC17F9C84FC</gtr:id><gtr:title>Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3770a1d59fe1e44f8c4d4a9f4f67a424"><gtr:id>3770a1d59fe1e44f8c4d4a9f4f67a424</gtr:id><gtr:otherNames>Pagano G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>588b5705840631.44130439</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC85AFE3-DAEB-425F-A83F-F0A81766419E</gtr:id><gtr:title>Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90b296d4baeb1674602f1bfcb122dc45"><gtr:id>90b296d4baeb1674602f1bfcb122dc45</gtr:id><gtr:otherNames>Mak E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56cc2dce4c0f87.76730774</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B06B34F5-CE68-4367-A980-90EE13C6443B</gtr:id><gtr:title>Psychogenic and neural visual-cue response in PD dopamine dysregulation syndrome.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e0f333502ce44c85b0ee264bbf20970"><gtr:id>1e0f333502ce44c85b0ee264bbf20970</gtr:id><gtr:otherNames>Loane C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn><gtr:outcomeId>56b4a402a5db68.24385903</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F6406EF5-6A58-4DD1-B0BD-2F752AA10105</gtr:id><gtr:title>Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimer's Disease and Parkinson's Disease Dementia?</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2c35d7bd686851bc183a51f1610d29ad"><gtr:id>2c35d7bd686851bc183a51f1610d29ad</gtr:id><gtr:otherNames>Femminella GD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>585d5237baa739.01527583</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E21558A6-EA0C-45D4-AE66-891FB59987F6</gtr:id><gtr:title>An early and late peak in microglial activation in Alzheimer's disease trajectory.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4752b222bbdee97e09071550d9255907"><gtr:id>4752b222bbdee97e09071550d9255907</gtr:id><gtr:otherNames>Fan Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>5a8ff4bc2ea755.00160975</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ADD045DC-6796-4A93-90DD-43AE869F6C87</gtr:id><gtr:title>Reversing the polarity of bipolar stimulation in deep brain stimulation for essential tremor: a theoretical explanation for a useful clinical intervention.</gtr:title><gtr:parentPublicationTitle>Neurocase</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2758b809c25b240b1178df52fdc91302"><gtr:id>2758b809c25b240b1178df52fdc91302</gtr:id><gtr:otherNames>Yousif N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1355-4794</gtr:issn><gtr:outcomeId>pm_15128_28_23003326</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A7A1C6E3-5E55-4211-8D0B-26C8D3296771</gtr:id><gtr:title>Age at onset and Parkinson disease phenotype.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3770a1d59fe1e44f8c4d4a9f4f67a424"><gtr:id>3770a1d59fe1e44f8c4d4a9f4f67a424</gtr:id><gtr:otherNames>Pagano G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a8ff7351b9885.19633329</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CFDDC784-2C1B-4AD6-B536-E5A02A369DB5</gtr:id><gtr:title>Do we still need to develop new imaging biomarkers of dopamine denervation for Parkinson's disease?</gtr:title><gtr:parentPublicationTitle>Experimental neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c62cf2e588e06d82be7991ac537b13"><gtr:id>90c62cf2e588e06d82be7991ac537b13</gtr:id><gtr:otherNames>Pavese N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0014-4886</gtr:issn><gtr:outcomeId>pm_15128_28_22036688</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E0A29918-E07C-4838-AEA5-9135300F9458</gtr:id><gtr:title>Imaging of genetic and degenerative disorders primarily causing Parkinsonism.</gtr:title><gtr:parentPublicationTitle>Handbook of clinical neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bc39481bfb591a878dc808e943f2de8"><gtr:id>9bc39481bfb591a878dc808e943f2de8</gtr:id><gtr:otherNames>Brooks DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0072-9752</gtr:issn><gtr:outcomeId>5a8ff6501df6f9.20768287</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4CC996CD-97A8-4D4B-A206-D247F40D4676</gtr:id><gtr:title>Dystonia: hopes for a better diagnosis and a treatment with long-lasting effect.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c62cf2e588e06d82be7991ac537b13"><gtr:id>90c62cf2e588e06d82be7991ac537b13</gtr:id><gtr:otherNames>Pavese N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>pm_15128_28_23436501</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>23C8F9EF-533E-4D20-98DC-D15C48F7821F</gtr:id><gtr:title>Chronic exposure to dopamine agonists affects the integrity of striatal Dreceptors in Parkinson's patients.</gtr:title><gtr:parentPublicationTitle>NeuroImage. Clinical</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/003ef0c2090080af16a9718d5168846f"><gtr:id>003ef0c2090080af16a9718d5168846f</gtr:id><gtr:otherNames>Politis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2213-1582</gtr:issn><gtr:outcomeId>5a8ff524b94675.80389097</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>53930F61-1E23-405C-B874-50B963F41A95</gtr:id><gtr:title>Initial evaluation of 18F-GE-179, a putative PET Tracer for activated N-methyl D-aspartate receptors.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e93cb976d5a49cb87347c23237e107a5"><gtr:id>e93cb976d5a49cb87347c23237e107a5</gtr:id><gtr:otherNames>McGinnity CJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>545798ddd110e1.26278729</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>56227FA8-252E-4966-B0FA-B924C9FE72E8</gtr:id><gtr:title>Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4752b222bbdee97e09071550d9255907"><gtr:id>4752b222bbdee97e09071550d9255907</gtr:id><gtr:otherNames>Fan Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>56b097179f5203.41261378</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>68360FB7-1908-4CD5-926C-2C2BC17B078D</gtr:id><gtr:title>Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a4fd269f8a153aaa555e0c7be89dc0c"><gtr:id>1a4fd269f8a153aaa555e0c7be89dc0c</gtr:id><gtr:otherNames>O'Sullivan SS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b4aec0df0e87.39587996</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0AA18F07-4196-4C43-B532-34311995C0F4</gtr:id><gtr:title>Spatiotemporal visualization of deep brain stimulation-induced effects in the subthalamic nucleus.</gtr:title><gtr:parentPublicationTitle>The European journal of neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2758b809c25b240b1178df52fdc91302"><gtr:id>2758b809c25b240b1178df52fdc91302</gtr:id><gtr:otherNames>Yousif N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0953-816X</gtr:issn><gtr:outcomeId>pm_15128_28_22805069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5DC3DDAD-D244-401E-92FE-9010B8024617</gtr:id><gtr:title>Imaging the aetiology of sleep disorders in dementia and Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Current neurology and neuroscience reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c62cf2e588e06d82be7991ac537b13"><gtr:id>90c62cf2e588e06d82be7991ac537b13</gtr:id><gtr:otherNames>Pavese N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1528-4042</gtr:issn><gtr:outcomeId>5457a532b5c228.14317476</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>83B32E1B-7D68-4208-93DB-B8A408C37D48</gtr:id><gtr:title>Characterizing mild cognitive impairment in incident Parkinson disease: the ICICLE-PD study.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9846543db4183f5f0ccf80c6f934e416"><gtr:id>9846543db4183f5f0ccf80c6f934e416</gtr:id><gtr:otherNames>Yarnall AJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>54579449418da3.39964069</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE5BCD37-BF72-40F8-B612-CFAB5C5D0C3D</gtr:id><gtr:title>Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/003ef0c2090080af16a9718d5168846f"><gtr:id>003ef0c2090080af16a9718d5168846f</gtr:id><gtr:otherNames>Politis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>5a8ff5921604c9.80623445</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>31A955BD-0976-4271-8A3F-91B0F6779F8E</gtr:id><gtr:title>Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/003ef0c2090080af16a9718d5168846f"><gtr:id>003ef0c2090080af16a9718d5168846f</gtr:id><gtr:otherNames>Politis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>54579412816a74.68692348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D2C884ED-C15E-442D-9A5F-5A56F042EEE3</gtr:id><gtr:title>PET Imaging in Huntington's Disease.</gtr:title><gtr:parentPublicationTitle>Journal of Huntington's disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/72effebdece862631d14369ee61bcd2c"><gtr:id>72effebdece862631d14369ee61bcd2c</gtr:id><gtr:otherNames>Roussakis AA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1879-6397</gtr:issn><gtr:outcomeId>56b4a3af2c1fc6.22842959</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B0084F8D-03D8-45AB-9E56-470CF7E02E02</gtr:id><gtr:title>Brain shaving: adaptive detection for brain PET data.</gtr:title><gtr:parentPublicationTitle>Physics in medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cb0d60f369b32844de70d46a1968ba59"><gtr:id>cb0d60f369b32844de70d46a1968ba59</gtr:id><gtr:otherNames>Grecchi E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0031-9155</gtr:issn><gtr:outcomeId>5457a57a8925e9.28879798</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A4E94C74-5D1A-4124-B206-8C90EE1789CF</gtr:id><gtr:title>PET studies in Parkinson's disease motor and cognitive dysfunction.</gtr:title><gtr:parentPublicationTitle>Parkinsonism &amp; related disorders</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/90c62cf2e588e06d82be7991ac537b13"><gtr:id>90c62cf2e588e06d82be7991ac537b13</gtr:id><gtr:otherNames>Pavese N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1353-8020</gtr:issn><gtr:outcomeId>pm_15128_28_22166468</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FBE419FD-8A1B-4A86-918A-C2BFA42FC3A4</gtr:id><gtr:title>Flutriciclamide (18F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4752b222bbdee97e09071550d9255907"><gtr:id>4752b222bbdee97e09071550d9255907</gtr:id><gtr:otherNames>Fan Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>5a8ff90017ea60.30446474</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A65D4FA6-F442-4CBC-8C23-4EFED7797C93</gtr:id><gtr:title>Progression of nonmotor symptoms in subgroups of patients with non-dopamine-deficient Parkinsonism.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/06b8bfbbf7c5f9349931d4f38f3cbde2"><gtr:id>06b8bfbbf7c5f9349931d4f38f3cbde2</gtr:id><gtr:otherNames>Taylor S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>5a8ff777bef277.23597722</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>70E360B4-7498-40C4-9F48-E90DB495B1F9</gtr:id><gtr:title>Serotonergic mediated body mass index changes in Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Neurobiology of disease</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/003ef0c2090080af16a9718d5168846f"><gtr:id>003ef0c2090080af16a9718d5168846f</gtr:id><gtr:otherNames>Politis M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0969-9961</gtr:issn><gtr:outcomeId>56b4ae571bca61.79767736</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7E8ACB5-1575-481D-B31B-3315B6146D18</gtr:id><gtr:title>Molecular imaging of dopamine transporters.</gtr:title><gtr:parentPublicationTitle>Ageing research reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9bc39481bfb591a878dc808e943f2de8"><gtr:id>9bc39481bfb591a878dc808e943f2de8</gtr:id><gtr:otherNames>Brooks DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1568-1637</gtr:issn><gtr:outcomeId>5a8ff7f0e13914.70687361</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>34790CC8-BE25-4BDB-BA86-1E3DAB012556</gtr:id><gtr:title>Using [(11)C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism.</gtr:title><gtr:parentPublicationTitle>NeuroImage</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdb2a9c9fc56464edeebc94d8161093c"><gtr:id>fdb2a9c9fc56464edeebc94d8161093c</gtr:id><gtr:otherNames>Lingford-Hughes A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1053-8119</gtr:issn><gtr:outcomeId>5a8ff6f054bad4.24380203</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CAFB425-2237-4949-96A0-D65E93AD0F5C</gtr:id><gtr:title>Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/687f3e72660ef07906615845fac8138f"><gtr:id>687f3e72660ef07906615845fac8138f</gtr:id><gtr:otherNames>Qamhawi Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b3701eaeacf1.99774893</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>225AA683-66A3-48D2-8DCC-DCB441C5FE8C</gtr:id><gtr:title>Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4752b222bbdee97e09071550d9255907"><gtr:id>4752b222bbdee97e09071550d9255907</gtr:id><gtr:otherNames>Fan Z</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>56b0927d5f1db5.08084347</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58D4AF92-B2F9-45BE-A3F8-6830A69D0D23</gtr:id><gtr:title>Genetic impact on cognition and brain function in newly diagnosed Parkinson's disease: ICICLE-PD study.</gtr:title><gtr:parentPublicationTitle>Brain : a journal of neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/cd26b1e138b12e934f0f4bc35f2a04be"><gtr:id>cd26b1e138b12e934f0f4bc35f2a04be</gtr:id><gtr:otherNames>Nombela C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0006-8950</gtr:issn><gtr:outcomeId>545782607adff1.88681935</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF5F5A39-9E07-42FA-AA97-81A50520B410</gtr:id><gtr:title>Amyloid pathology and axonal injury after brain trauma.</gtr:title><gtr:parentPublicationTitle>Neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/071e882d6d5617fac73b55ac1d8145b1"><gtr:id>071e882d6d5617fac73b55ac1d8145b1</gtr:id><gtr:otherNames>Scott G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0028-3878</gtr:issn><gtr:outcomeId>5a8ff7b66134e5.99030161</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A19D4FA5-6AFE-4D72-B5EC-C16EAAD6DEF8</gtr:id><gtr:title>Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms.</gtr:title><gtr:parentPublicationTitle>Movement disorders : official journal of the Movement Disorder Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9d5ff3112eb4c8114965fb4425fcde55"><gtr:id>9d5ff3112eb4c8114965fb4425fcde55</gtr:id><gtr:otherNames>Duncan GW</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0885-3185</gtr:issn><gtr:outcomeId>545799fa8f29e5.56154283</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1100810</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>